Blackstone just locked in a hefty $765 million refinance for one of Boston’s biggest lab towers, the Center for Life Science at 3 Blackfan Circle in the Longwood Medical Area. The high-rise research and office complex is fully leased to heavyweight medical and research institutions, and the deal is a reminder that top-tier lab buildings with blue-chip tenants can still draw serious lender interest even as biotech funding cools across the country.
According to CoStar, the loan was structured as a commercial mortgage-backed securities package, with BioMed Realty, Blackstone’s life science platform, listed as the borrower. CoStar, which reported the transaction on May 4, 2026, noted that the Center is 100% occupied and leased largely to investment-grade medical and research tenants. Public reports so far have not identified the lender group or detailed the loan’s pricing.
What’s in the building
The Center for Life Science at 3 Blackfan Circle was built to deliver lab-ready space tailored to Longwood’s hospitals and research institutions. It houses tenants that include Beth Israel Deaconess, Boston Children's Hospital and the Dana-Farber Cancer Institute, according to property materials and tenant directories. Lyme Properties and Boston Children's Hospital both list the Center for Life Science at that address and highlight it as a major research hub. The tower was designed as a multi-tenant, lab-ready building and has served as a key anchor in the Blackfan and Longwood research district since it opened.
Why the refinance matters
CoStar notes that the deal comes as the national biotech market has weakened, a backdrop that has made financing trickier for many lab owners. At the same time, Blackstone has been doubling down on life sciences, recently announcing the final close of a $6.3 billion Blackstone Life Sciences fund, which signals that the sector remains a strategic focus for the firm. BioMed has a history of using CMBS and other securitization vehicles in its financings, according to securities filings on earlier BioMed offerings, so this structure fits a familiar playbook rather than a wild swing.
What it means for Longwood
For landlords and tenants in Longwood, a refinance of this size is a strong vote of confidence. It suggests that buildings with long-term, investment-grade tenants can still tap large capital pools even when the broader lab market feels choppier. City and market reports have flagged shifting vacancy rates and changing construction pipelines in Greater Boston’s lab sector, which makes stability at trophy addresses like 3 Blackfan Circle especially prized. The new debt package should give BioMed and Blackstone more room to maneuver at the property level and ease near-term pressure from loan maturities tied to the asset.
Details such as exact pricing, lender participation and covenant terms typically surface later in CMBS prospectuses and loan-level filings. Those documents, along with subsequent securities disclosures, are expected to lay out the loan’s term, rate structure and any special servicing provisions. We will be watching those filings as they are released to see who ultimately lined up behind this $765 million lifeline and on what terms.
